CJC-1295

CJC-1295 (without DAC), also called Modified GRF 1-29, is a tetrasubstituted analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). The substitutions protect it from enzymatic degradation, extending its half-life to roughly 30 minutes.

CJC-1295 is the short-acting GHRH analog that asks the pituitary for a clean, natural-shaped pulse of growth hormone. It is the version most researchers pair with ipamorelin for that classic 'pulse-on-pulse' GH protocol.

Binds GHRH receptors on pituitary somatotrophs, triggering pulsatile endogenous GH release. The four amino-acid substitutions block dipeptidyl peptidase-IV cleavage without changing receptor binding, giving it a useful half-life while preserving natural pulsatility.

Short-acting GHRH analog. Mimics natural pulsatile GH release.

1. CJC-1295
2. GHRH and/or ghrelin receptors in the pituitary
3. Pulsatile growth hormone release
4. Downstream IGF-1, body-composition and recovery endpoints

A plain-English read on how much published evidence currently exists for CJC-1295. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of CJC-1295.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

2mg or 5mg vial

Worked concentration example

2mg + 2mL BAC water → 1mg/mL On U-100 insulin syringe:

• • 10 units = 100mcg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

100mcg, 2–3× daily subcutaneous

Commonly cited frequency

2–3× daily — paired in same syringe with Ipamorelin

Commonly cited study duration

8–12 weeks

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •GH and IGF-1 release studies
• •Pulsatile vs sustained GH research
• •CJC-1295 + Ipamorelin synergy
• •Body composition research
• •Comparison with Sermorelin and Tesamorelin

The default 'mod GRF' in research forums. People consistently debate CJC-1295 (no DAC) vs CJC-1295 DAC: the no-DAC version is preferred when researchers want to preserve natural GH pulsatility; the DAC version is preferred for steady elevation.

“The clean, short-pulse GHRH analog.”

Almost universally stacked with Ipamorelin for the canonical 'CJC + Ipa' GH pulse. Compared to Sermorelin (shorter half-life), CJC-1295 DAC (much longer half-life), and Tesamorelin (visceral-fat focus).

CJC-1295 (Modified GRF 1-29) is a short-acting GHRH analog studied for pulsatile endogenous GH release, most often paired with Ipamorelin.